Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

56.50
+0.03000.05%
Volume:1.15M
Turnover:65.16M
Market Cap:10.80B
PE:-13.80
High:57.48
Open:56.63
Low:55.71
Close:56.50
52wk High:57.48
52wk Low:21.72
Shares:191.17M
Float Shares:151.20M
Volume Ratio:0.47
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0935
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-41.96%
PB:-6.04
PE(LYR):-19.62

Loading ...

BridgeBio Oncology Therapeutics Announces Poster Presentations on Novel KRAS Inhibitors at 2025 AACR-NCI-EORTC Conference

Reuters
·
Oct 14

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Oct 11

BRIEF-BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Oct 04

BridgeBio Pharma Announces Equity Grants for New Employees Under Amended Inducement Equity Plan

Reuters
·
Oct 04

BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month

MT Newswires Live
·
Sep 29

BridgeBio presented data from ATTRibute-CM study on acoramidis

TIPRANKS
·
Sep 29

BridgeBio Pharma Inc. Publishes Report on State-Level Differences in Incidence of ATTR-CM Among U.S. Veterans

Reuters
·
Sep 29

BRIEF-BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

Reuters
·
Sep 28

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients With Attr-Cm

THOMSON REUTERS
·
Sep 28

BridgeBio Pharma Inc - Acoramidis Reduces Cvm or Cvh Risk by 49% Through Month 30

THOMSON REUTERS
·
Sep 28

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

GlobeNewswire
·
Sep 28

BridgeBio Pharma Inc. Publishes Data on Acoramidis’ Effect on Cardiovascular Mortality and Hospitalization in ATTR-CM

Reuters
·
Sep 28

BridgeBio Pharma Inc. Publishes Report on Transthyretin Amyloid Cardiomyopathy Study

Reuters
·
Sep 27

BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025

Reuters
·
Sep 22

BridgeBio Pharma Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 15

BridgeBio Pharma Is Maintained at Buy by UBS

Dow Jones
·
Sep 12

BridgeBio price target raised to $82 from $72 at UBS

TIPRANKS
·
Sep 12

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $64 From $62

THOMSON REUTERS
·
Sep 11

BridgeBio Pharma Announces New Equity Compensation Plan for Employees with Inducement Grants

Reuters
·
Sep 11

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 11